1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T cell dependent tumor immunity.
Mangsbo, Sara M ; Broos, Sissela LU ; Fletcher, Erika ; Veitonmaki, Niina ; Furebring, Christina ; Dahlen, Eva ; Norlén, Per LU ; Lindstedt, Malin LU
; Totterman, Thomas H
and Ellmark, Peter
LU
(2015)
In Clinical Cancer Research
21(5).
p.1115-1126
- Contribution to journal › Article
- 2010
-
Mark
Development of a C5AR antagonist for the treatment of reperfusion injury
Dahlen, Eva ; Gustafsson, Erika ; Larsson, Bengt ; van der Pals, Jesper ; Erlinge, David LU
and Furebring, Christina
(2010)
8th Joint Conference of the International-Cytokine-Society/International-Society-for-and-Cytokine-Re search
In Cytokine
52(1-2).
p.26-26
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis.
- Contribution to journal › Article
- 2000
-
Mark
Antigen presenting cells in autoimmune diabetes: phenotype, function and modulation by Linomide
(2000)
- Thesis › Doctoral thesis (compilation)